Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Rises By 112.5%

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,800 shares, an increase of 112.5% from the December 31st total of 3,200 shares. Based on an average daily volume of 16,400 shares, the days-to-cover ratio is presently 0.4 days.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 price target on shares of Adlai Nortye in a report on Monday, November 11th.

Adlai Nortye Stock Up 3.2 %

NASDAQ ANL traded up $0.07 during trading hours on Friday, reaching $2.13. The company’s stock had a trading volume of 1,603 shares, compared to its average volume of 11,598. The firm’s 50-day moving average price is $2.18 and its 200-day moving average price is $2.47. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.